Cardio-Endo-Renal Collaborative (CERC) Clinical Connections™

Released On
December 14, 2018

Expires On
December 14, 2019

Media Type

Completion Time
120 minutes

Cardiology, Case Management, Endocrinology, Emergency Medicine, Nephrology, Pulmonology, Sleep Medicine

Cardio-Endo-Renal Collaborative

Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by Global Education Group and Physicians’ Education Resource®, LLC.

Supported by an educational grant from Actelion Pharmaceuticals US, Inc, Novartis Pharmaceuticals Corporation, Sanofi US, and Regeneron Pharmaceuticals.

Credit Available

  • Physicians — maximum of 2.0 AMA PRA Category 1 Credit(s)
  • Nurses — 2.0 contact hours.

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This educational activity is directed toward cardiologists, endocrinologists, specialty nurse practitioners, specialty physician assistants, certified diabetes educators, other specialty allied health professionals, nephrologists, and other healthcare professionals.

Program Overview

CARDIO-ENDO-RENAL COLLABORATIVE (CERC) Clinical Connections™ focuses on the theme of Novel Approaches to Integrated Cardiometabolic Disease Management. This activity encompasses advancements in novel therapies and technologies, lifestyle medicine, multidisciplinary approaches that are driving improvements in outcomes and quality, and cardiovascular (CVD)/metabolic disease prevention. CERC Clinical Connections™ highlights clinical updates and strategies aimed directly at the intersection of metabolic and CVD prevention. Clinically relevant topics in cardiometabolic health include CVD prevention, dyslipidemia, heart failure, and pulmonary arterial hypertension. This clinical connection will provide healthcare professionals clinical insight and advance their understanding of chronic cardiometabolic diseases and associated comorbidities.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Recognize the reduction of cardiovascular risk associated with anti-inflammatory therapy in patients with a well-established inflammatory risk assessment
  • Evaluate individualization of chronic heart failure treatment based on patient-specific factors to reduce morbidity/mortality with the use of guideline-recommended therapy
  • Translate clinical trial data to clinical practice for successful implementation, when appropriate, of a PCSK9 inhibitor to current therapeutic regimens for patients exhibiting statin intolerance or minimal change in LDL-C levels, despite use of maximally tolerated dose of statins
  • Identify pulmonary arterial hypertension to prevent delays in diagnosis, and to promptly apply evidence-based, guideline-recommended therapy to improve symptoms and quality of life



Lipidology & Cardiovascular Disease Prevention
Clinical Assistant Professor of Medicine
NYU Medical School & NYU Center for CV Prevention
Director, Bellevue Hospital Lipid Clinic
Past-President, National Lipid Association
New York, NY

Keith C. Ferdinand, MD, FACC, FAHA, FNLA, FASH

Professor of Medicine
Tulane University School of Medicine
Tulane Heart and Vascular Institute
New Orleans, LA

Paul M. Ridker, MD, MPH, FACC, FAHA

Eugene Braunwald Professor of Medicine
Harvard Medical School
Director, Center for Cardiovascular Disease Prevention
Brigham and Women's Hospital
Boston, MA

Roxana Sulica, MD

Associate Professor, Department of Medicine
Director, Pulmonary Hypertension Program
NYU Langone Health
New York, NY

Physician Accreditation Statement

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians

Physician Credit Designation

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest


  • Grant/Research Support: Aegerion, Pfizer
  • Consultant: Amgen, Amarin
  • Speakers Bureau: Amgen, Amarin, Akcea, Alexion, Sanofi, Regeneron
  • Advisory Board: Amgen, Sanofi, Regeneron, Akcea, Aegerion, Alexion, Ambry

Keith C. Ferdinand, MD, FACC, FAHA, FNLA, FASH

  • Consultant: Amgen, Sanofi, Boehringer Ingelheim, Janssen, Quantum Genomics

Paul M. Ridker, MD, MPH, FACC, FAHA

  • Grant/Research Support: National Heart, Lung, and Blood Institute, National Cancer Institute, American Heart Association, Doris Duke Charitable Foundation, Leducq Foundation, Donald W. Reynolds Foundation, James and Polly Annenberg La Vea Charitable Trusts, AstraZeneca, Novartis, Pfizer, Kowa, Amgen
  • Consultant: Quintiles, Novartis, Corvidia, lnflazome, Eisai, Sanofi, Janssen
  • Other: Investigational/off-label use of drugs/device disclosures: canakinumab and methotrexate
  • Dr. Ridker is listed as a co-inventor on patents held by the Brigham and Women's Hospital that relate to the use of inflammatory biomarkers in cardiovascular disease that have been licensed to Siemens and AstraZeneca.

Roxana Sulica, MD

  • Grant/Research Support: Reata
  • Consultant: Actelion, Bayer, Arena, United Therapeutics

The staff of Physicians' Education Resource®, LLC, (PER®) have no relevant financial relationships with commercial interests to disclose.

Method of Participation

Instructions for This Activity and Receiving Credit

  1. You will need to log in to participate in the activity.
  2. Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  3. At the end of the activity, educational content/audio files will be available for your reference.
  4. In order to receive a CME/CE certificate, you must complete the activity.
  5. Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE certificate upon completion of these steps.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.